GenePOC Inc. has announced that it signed distribution agreements with 8 partners across Europe for the commercialization of its first products. This is a key Milestone in the development of GenePOC and the timing fits well with the timeline announced earlier to start commercialization in autumn of 2016. The commercial partners signed up are Astra Formedic S.r.l.in Italy, bestbion dx GmbH in Germany/Austria, Biosynex Group in France, EMM Life Science AB in Sweden/Denmark/Finland/Norway/Iceland, Fannin Ltd in Ireland, Mediphos Group BV in Netherlands/Belgium/Luxembourg, Near Patient Diagnostics Ltd. in the UK and Vitro S.A.B. de C.V. in Spain/Portugal.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.2 EUR | -0.47% | +2.69% | -49.70% |
30/04 | Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
29/04 | Biosynex: agreement for ProciseDx in North America | CF |
1st Jan change | Capi. | |
---|---|---|
-49.70% | 48.69M | |
-1.89% | 12.56B | |
-9.59% | 7.68B | |
-1.31% | 5.29B | |
+21.82% | 5.18B | |
+0.02% | 4.57B | |
-50.89% | 3.29B | |
+6.42% | 2.6B | |
-10.02% | 2.2B | |
-8.29% | 1.79B |
- Stock Market
- Equities
- ALBIO Stock
- News Biosynex
- GenePOC, Inc. Announces Setup of an Extensive Network of Commercial Partners Across Europe for Distribution